Scarica l'app Stockscreener
0.9714
1.82%
0.0174
Dopo l'orario di chiusura:
.95
-0.0214
-2.20%
Senti Biosciences Holdings Inc Borsa (SNTI) Ultime notizie
Celadon backs Senti Biosciences (SNTI) with $40M notes and majority stake - Stock Titan
Senti Biosciences Secures Convertible Note Financing with Celadon - TipRanks
Senti Biosciences Holdings (NASDAQ: SNTI) continues $17.5M ATM program - Stock Titan
Senti Biosciences Strikes Up to $40 Million Secured Convertible Notes Financing With Celadon - TradingView
Celadon-led $40M notes could give Senti (NASDAQ: SNTI) majority holder - Stock Titan
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
Senti Biosciences 2025 Executive Compensation, Officer Employment Arrangements, and Stock Awards Overview - Minichart
[EFFECT] Senti Biosciences, Inc. SEC Filing - Stock Titan
Senti Biosciences (NASDAQ: SNTI) files 10-K/A on 2025 pay, board and ownership - Stock Titan
Senti Biosciences Holdings, Inc.: Financial Data Forecasts Estimates and Expectations | SNTI | US8169441024 - marketscreener.com
Senti Biosciences (NASDAQ: SNTI) adopts S-3 post-merger reorganization - Stock Titan
Senti Biosciences Holdings (SNTI) adopts S-3 after April 24, 2026 merger - Stock Titan
Senti Biosciences completes holding company reorganization, stock continues on Nasdaq - Investing.com
Senti Biosciences (NASDAQ: SNTI) deregisters 8.7M shares previously for resale - Stock Titan
SNTI Senti Biosciences Inc. shares rise nearly 14 percent even as Q4 2025 EPS misses Wall Street estimates. - Cổng thông tin điện tử tỉnh Tây Ninh
Senti Biosciences (SNTI) Stock: Why You Should Avoid It (Bullish Sentiment) 2026-04-20Aggressive Growth Stocks - Xã Vĩnh Công
Senti Biosciences (SNTI) Stock 52-Week Low (Rocket Higher) 2026-04-18Community Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Senti Biosciences Q4 Operating Income USD -18 - Moomoo
[SCHEDULE 13D/A] Senti Biosciences, Inc. Amended Major Shareholder Report - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Bioscie - The National Law Review
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - Bitget
Cancer conference session will showcase Senti Bio's cell therapy approach - Stock Titan
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial - TradingView
Is Senti Biosciences (SNTI) Stock Trading at Fair Value | Price at $0.87, Up 1.55%Street Ratings - Cổng thông tin điện tử Tỉnh Sơn La
Growth Review: Will Senti Biosciences Inc outperform small cap indexes2026 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
SNTI Q4 2025 Earnings: Senti Biosciences Inc. misses EPS estimates, no Q4 revenue - Newser
Senti Biosciences, Inc. Files Form 8-K Cover Report with NASDAQ Listing Details (April 1, 2026) - Minichart
Senti Biosciences plans holding company reorganization, stock to continue under SNTI - Investing.com India
Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026SEC Filing - TradingView
Senti Biosciences announces holding company reorganization effective by April 16, 2026SEC filing - marketscreener.com
Senti Biosciences Plans Tax-Free Holding Company Reorganization - TipRanks
Senti Biosciences, Inc. has filed documents with the U.S. Securities and Exchange Commission, officially announcing a holding company reorganization plan. - Bitget
Senti Bios to implement tax-free holding company reorganization, shares to convert and continue trading as SNTI - TradingView — Track All Markets
Holding company reorg keeps Senti (NASDAQ: SNTI) stock structure intact - Stock Titan
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies - Bitget
Senti Biosciences publishes CAR circuit research in Cell Systems - Investing.com
Senti Biosciences publishes CAR circuit research in Cell Systems By Investing.com - Investing.com India
Senti Biosciences (SNTI) holder NEA discloses 3.78M-share, 12.1% stake - Stock Titan
Senti Biosciences (NASDAQ:SNTI) Price Target Cut to $11.00 by Analysts at Chardan Capital - Defense World
SNTI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Buy Rating on SENTI-202 Driven by Strong Early AML Efficacy and De-Risking Regulatory Designations Despite Financing Overhang - TipRanks
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Senti Biosciences, Inc. (SNTI) Reports Q4 Earnings - AlphaStreet
Senti Biosciences stock rating held at Buy by H.C. Wainwright - Investing.com Canada
Senti Biosciences stock rating held at Buy by H.C. Wainwright By Investing.com - Investing.com India
Senti Biosciences (NASDAQ: SNTI) advances SENTI-202 gene circuit CAR-NK program - Stock Titan
Senti Biosciences 10-K: Collaboration revenue $0.022M, Net loss $61.44M, EPS $(2.73) - TradingView
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
Senti Biosciences Q4 revenue misses analyst estimates - tradingview.com
SNTI: Positive SENTI-202 clinical progress, RMAT status, and $61.4M net loss with $16.4M cash - TradingView
Senti Bio (NASDAQ: SNTI) posts 2025 loss as SENTI-202 gains FDA RMAT - Stock Titan
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):